Details of the Drug Reposition

General Information of This Drug (ID: DM4NY58)

Drug Name
SB-623   DM4NY58
Synonyms (E)-3-[1-(2-diethylaminoethyl)-2-phenethylbenzimidazol-5-yl]-N-hydroxyprop-2-enamide
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ischemic stroke DISYV7YJ 8B11.5Z Phase 2 [1]
Cerebrovascular ischaemia DISFSDLO 8B1Z Phase 2 [2]
Stroke DISX6UHX 8B20 Phase 2 [3]
Traumatic brain injury DISN8K9H NA07.Z Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02448641) Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)